Beta-Blocker in Acute Decompensated Heart Failure
A 72-year-old man with HFrEF (EF 28%) on carvedilol 12.5 mg BID, sacubitril/valsartan, spironolactone, and furosemide presents with 3 days of worsening dyspnea. He is orthopneic, has bibasilar crackles to mid-lung, JVP elevated, and 2+ bilateral edema. BP 98/62 mmHg, HR 88 bpm, SpO2 90% on room air. Creatinine 1.9 mg/dL (baseline 1.3), potassium 5.1 mmol/L. He gained 4 kg. He is not in cardiogenic shock, has no altered mentation, and is making urine. The resident asks whether to stop carvedilol, hold sacubitril/valsartan, and whether spironolactone should continue given the potassium.
1. Should carvedilol be discontinued, held, or continued? Justify using the physiology of decompensation.
Read the worked answer
Continue carvedilol at the current dose in this patient. He is not in cardiogenic shock, is hemodynamically stable (BP 98/62, HR 88, adequate mentation, making urine), and beta-blockade is a mortality-reducing therapy in HFrEF. Abrupt discontinuation risks rebound tachycardia, ischemia, and arrhythmia, and is associated with worse outcomes. The exam distinction: beta-blockers are held or reduced in cardiogenic shock, severe hypotension, symptomatic bradycardia, or worsening congestion attributable to the beta-blocker. Here the decompensation is volume/afterload-driven, not beta-blocker-driven. The correct action is to treat the congestion (increase diuresis) rather than withdraw a disease-modifying drug. Nuance: if hypotension becomes limiting or the patient develops low-output signs, reduce the dose; do not stop abruptly. Down-titration, not discontinuation, is the fallback.
2. Address the sacubitril/valsartan and spironolactone decisions, including the potassium and creatinine changes. What monitoring would you order?
Read the worked answer
Sacubitril/valsartan: Hold or reduce during acute decompensation with hypotension (BP 98/62) and AKI (Cr 1.9 from 1.3). ARNI/ACEi/ARB are typically held in acute decompensated HF with hypotension or worsening renal function, then restarted once euvolemic and stable. Do not restart until BP and renal function recover. Spironolactone: K 5.1 with AKI is a relative contraindication. MRA raises hyperkalemia risk, especially with reduced eGFR and concurrent ARNI. Hold spironolactone until K < 5.0 and renal function improves; recheck K and Cr in 24–48 h. Monitoring: daily BMP (K, Cr, Mg), daily weights, strict I/O, renal function before/after diuretic escalation, and reassess BP. Consider whether loop diuretic dose needs increase for the 4 kg gain. The teaching point: in ADHF, hold RAAS/MRA agents that worsen hypotension/hyperkalemia/AKI, but continue beta-blockers unless shock or rate-limiting bradycardia.